A Look At IQVIA Holdings (IQV) Valuation After Charles River Deal And Fresh Analyst Coverage

robot
摘要生成中

IQVIA Holdings (IQV) is gaining investor attention following a planned acquisition of Charles River Laboratories’ discovery services assets and new analyst coverage. Despite recent positive share price movements, longer-term returns have been weaker. The company is currently considered 31.4% undervalued, with a narrative fair value of $250.00, driven by a record R&D Solutions backlog and strong demand for outsourced clinical research, particularly in specialized therapeutic areas.

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论